Lv61
1730 积分 2022-08-19 加入
Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products
20天前
已完结
Stability of intravenous antibody dilutions in clinical use: Differences across patient populations with varying body weights
23天前
已完结
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
23天前
已完结
ITP-BAT出血评分系统在原发免疫性血小板减少症的临床应用价值
1个月前
已完结
A manganese-oxide nano-rambutan as the intrinsic modifier for hypericin delivery and triple-negative breast cancer treatment
1个月前
已完结
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
1个月前
已完结
Protein Adsorption of In-line Intravenous Infusion Filter and the Corresponding Mitigation Plans
2个月前
已关闭
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
2个月前
已完结
SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation
2个月前
已完结
SLEDAI-2K for a 30-day window
2个月前
已完结
皖公网安备34019202002308
